Medicenna Hits Enrollment Milestone in Global ABILITY‑1 IL‑2 Trial, Boosting Immuno‑Oncology Hope
Medicenna Therapeutics reaches a key milestone: full enrollment of 152 patients in its global Phase 1/2 ABILITY‑1 trial of the IL‑2 Superkine MDNA11, positioning the drug as a promising next‑generation immuno‑oncology therapy.
3 minutes to read
